Hiroyuki Murai
A5077281690- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Parkinson's Disease and Spinal Disorders
- Multiple Sclerosis Research Studies
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Prion Diseases and Protein Misfolding
- Autoimmune Neurological Disorders and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Hereditary Neurological Disorders
- Immune Response and Inflammation
- Pituitary Gland Disorders and Treatments
- Dermatology and Skin Diseases
- Neurogenetic and Muscular Disorders Research
- Cerebrovascular and Carotid Artery Diseases
- Acute Ischemic Stroke Management
- Inflammatory Myopathies and Dermatomyositis
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune Bullous Skin Diseases
- Mitochondrial Function and Pathology
- IgG4-Related and Inflammatory Diseases
- interferon and immune responses
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Systemic Lupus Erythematosus Research
- Intracerebral and Subarachnoid Hemorrhage Research
International University of Health and Welfare
2017-2025
Mita Hospital
2019-2024
Kubota (Japan)
2024
Toho University Ohashi Medical Center
2024
Toho University
2024
Tokyo Medical University
2024
Keio University
2024
Japan Pediatric Society
2024
Alexion Pharmaceuticals (France)
2024
Kyushu University
2009-2023
There are two distinct subtypes of multiple sclerosis in Asians, opticospinal (OS-multiple sclerosis) and conventional (C-multiple sclerosis). In OS-multiple sclerosis, selective severe involvement the optic nerves spinal cord is characteristic, though its mechanisms unknown. The present study aimed to find out possible differences cytokine/chemokine profiles CSF between C-multiple delineate relationships these neuroimaging pathological features. Sixteen cytokines/chemokines, namely...
Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of open-label extension REGAIN, evaluating eculizumab's long-term safety efficacy.Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients.The profile eculizumab consistent no cases meningococcal infection were reported during the period. Myasthenia...
Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), the relationships of these clinical neuroimaging features are unclear. A greater understanding may help differential diagnosis.We measured 27 cytokines/chemokines growth factors CSF collected from 20 NMO, 26 RRMS, nine PPMS, 18 other non-inflammatory neurological diseases (OND) by multiplexed fluorescent bead-based...
To investigate anti-neurofascin 155 (NF155) antibody-positive chronic inflammatory demyelinating polyneuropathy (CIDP).Sera from 50 consecutive CIDP patients diagnosed in our clinic, 32 with multiple sclerosis, 40 other neuropathies including 26 Guillain-Barré syndrome (GBS)/Fisher syndrome, and 30 healthy controls were measured for anti-NF antibodies by flow cytometry using HEK293 cell lines stably expressing human NF155 or NF186. Four additional anti-NF155 referred clinics enrolled...
Corona Virus Disease 2019 (COVID-19) is a new illness caused by novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms are variable but typically include fever, cough, symptoms, diarrhea, reduction of smell and taste sensation. Severity ranges from mild to the virus may lead pneumonia, distress death, in some patients. Nearly every country world has been affected this currently defined as pandemic, World Health Organization. There no known proven therapies...
Objective ADAPT+ assessed the long-term safety, tolerability, and efficacy of efgartigimod in adult participants with generalized myasthenia gravis (gMG). Methods was an open-label, single-arm, multicenter, up to 3-year extension pivotal phase 3 ADAPT study. Efgartigimod administered treatment cycles 4 intravenous infusions (one 10 mg/kg infusion per week). Initiation subsequent individualized based on clinical evaluation. Safety endpoints included incidence severity adverse events. Efficacy...
The amyloid beta-protein (Abeta) ending at 42 plays a pivotal role in Alzheimer's disease (AD). We have reported previously that intracellular Abeta42 is associated with neuronal apoptosis vitro and vivo. Here, we show directly activated the p53 promoter, resulting p53-dependent apoptosis, Abeta40 had similar but lesser effect. Moreover, oxidative DNA damage induced nuclear localization of mRNA elevation guinea-pig primary neurons. Also, expression was elevated brain sporadic AD transgenic...
We analysed the epidemiological data and clinical features of patients with prion diseases that had been registered by Creutzfeldt-Jakob Disease Surveillance Committee, Japan, over past 10 years, since 1999. obtained information on 1685 Japanese suspected as having judged 1222 diseases, consisting definite (n = 180, 14.7%) probable 1029, 84.2%) cases, except for dura mater graft-associated Creutzfeldt–Jakob disease which also included possible cases 13, 1.1%). They were classified into 922...
We aimed to identify the target antigens for combined central and peripheral demyelination (CCPD).We screened by immunohistochemistry immunoblotting using nerve tissues recognized serum antibodies from selected CCPD chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) cases. then measured level of antibody relevant antigen in 7 patients with CCPD, 16 CIDP, 20 multiple sclerosis, Guillain-Barré syndrome, 21 other neuropathies, 23 healthy controls (HC) ELISA cell-based assays...
<h3>Objectives</h3> To clarify the prevalence, frequent causes and distinct features of hypertrophic pachymeningitis (HP) according to background conditions in a nationwide survey Japan. <h3>Methods</h3> The study began with preliminary determine approximate number HP patients diagnosed from 1 January 2005 31 December 2009, was followed by questionnaire for clinical laboratory findings. defined as condition thickening cranial or spinal dura mater inflammation, evidenced MRI histology....
Introduction The definitive diagnosis of genetic prion diseases (gPrD) requires pathological confirmation. To date, has relied upon the finding biomarkers 14-3-3 protein and total tau (t-tau) in cerebrospinal fluid (CSF), but many researchers have reported that these markers are not sufficiently elevated gPrD, especially Gerstmann-Sträussler-Scheinker syndrome (GSS). We recently developed a new vitro amplification technology, designated "real-time quaking-induced conversion (RT-QUIC)", to...
The MG-QOL15 is a validated, health-related quality of life (HRQOL) measure for myasthenia gravis (MG). Widespread use the scale gave us opportunity to further analyze its clinimetric properties. We first performed Rasch analysis on >1,300 15-item Myasthenia Gravis Quality Life (MG-QOL15) completed surveys. Results were discussed during conference call with specialists and biostatisticians. decided revise 3 items prospectively evaluate revised (MG-QOL15r) using either 3, 4, or 5 responses....
During the COVID-19 pandemic, patients with neuromuscular disorders, especially autoimmune myasthenia gravis, might be at greater risk of worse outcomes than otherwise healthy people because an immunocompromised state related to immunotherapy and possible respiratory bulbar muscular weakness. However, cessation in neuroinflammatory disorders has severe risks as well.1Korsukewitz C Reddel SW Bar-Or A Wiendl H Neurological era COVID-19—looking for consensus literature.Nat Rev Neurol. 2020; 16:...
Abstract The revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) were published in 2022. notable points these (GLs) are as follows: (i) the first GLs to include a description of LEMS; (ii) diagnostic criteria MG lessen incidence false negative patients; (iii) is divided into six subtypes; (iv) high‐dose oral steroid regimen with escalation de‐escalation schedule not recommended by GLs; (v) promote early fast‐acting treatment strategy...
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) seronegative MG. We report details use efgartigimod MG clinical practice Japan.
Hashimoto's encephalopathy (HE) is a rare autoimmune disease associated with thyroiditis (HT). To identify the HE‐related autoantigens, we developed human brain proteome map using two‐dimensional electrophoresis and applied it to immuno‐screening of proteins that react autoantibodies in HE patients. After sequential MALDI‐TOF‐MASS analysis, immuno‐positive spots 48 kDa (p I 7.3–7.8) detected from patient sera were identified as novel autoimmuno‐antigen, α‐enolase, harboring several...
<h3>Objectives</h3> To clarify the clinical features of combined central and peripheral demyelination (CCPD) via a nationwide survey. <h3>Methods</h3> The following characteristics were used to define CCPD: T2 high-signal intensity lesions in brain, optic nerves or spinal cord on MRI, abnormalities visual-evoked potentials; conduction delay, block, temporal dispersion F-wave suggesting demyelinating neuropathy based nerve studies; exclusion secondary demyelination. We conducted survey 2012,...